This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Find out more here.

DRAKO Non-interventional Study

  • Research type

    Research Study

  • Full title

    DRAKO-An observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in patients with visual impairment due to diabetic macular oedema(DMO)

  • IRAS ID

    183403

  • Contact name

    Sobha Sivaprasad

  • Contact email

    Senswathi@aol.com

  • Sponsor organisation

    Bayer Plc

  • Duration of Study in the UK

    3 years, 0 months, 2 days

  • Research summary

    The purpose of this observational study is to obtain information on how effective aflibercept (Eylea®) is in real life clinical settings and how it is actually being used in clinics. Aflibercept is already licensed (approved by the UK medicines regulatory authority).
    The study will involve approximately 750 patients who are undergoing aflibercept treatment for Diabetic Macular Oedema (DMO) in approximately 30 study centres located throughout the United Kingdom.

  • REC name

    North West - Liverpool East Research Ethics Committee

  • REC reference

    16/NW/0238

  • Date of REC Opinion

    23 Mar 2016

  • REC opinion

    Favourable Opinion